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Footnotes:  
Abbreviations and notations used throughout the text, tables and figures are defined as follows: 
ABC: ATP-binding cassette; ADME: absorption, distribution, metabolism, and excretion; AUC: 
area under the curve; BCRP (ABCG2): breast cancer resistance protein; BEI: biliary excretion 
index; BSEP (ABCB11): bile salt export pump; CHO: Chinese Hamster Ovary cells; CLbile, app: 
apparent biliary excretion clearance from medium to bile; CLbile, int: intrinsic biliary excretion 
clearance from cell to bile; CLuptake: uptake clearance; DDI: drug-drug interaction; FRT: Flp 
Recombination Target; GST: glutathione S-transferase; HEK-293: human embryonic kidney 
cells; IC50: concentration of inhibitor required to achieve 50% inhibition; Ki: inhibition constant; 
Km: Michaelis-Menten constant; Kpuu: hepatocyte-to-medium partition coefficient for unbound 
drug concentration; LLC-PK1: Porcine Kidney proximal tubule epithelial cells; MDCK or MDCKII: 
Madin-Darby canine kidney cells; MATE (SLC47A): multidrug and toxin extrusion protein; MDR1 
P-gp (ABCB1): multi-drug resistance 1 P-glycoprotein; MRP (ABCC): multidrug resistance 
protein; NTCP (SLC10A1): Na+-taurocholate co-transporting polypeptide; OAT (SLC22A): 
organic anion transporter; OATP (SLCO): organic anion transporting polypeptide; OCT 
(SLC22A): organic cation transporter; Papp: apparent permeability; PBPK: physiologically based 
pharmacokinetic; SCH: sandwich-cultured hepatocytes; Sf9 or Sf21: Spodoptera frugiperda 
insect cells; UGT: UDP-glucuronosyltransferase; Vmax: maximum transport or metabolic rate  
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Introduction  
 
This whitepaper addresses current approaches and knowledge gaps concerning 
methods to assess the role of transport proteins in drug/metabolite disposition in 
humans. Discussion focuses on in vitro tools to address key questions in drug 
development, including vesicle and cell-based systems.  How these methods can be 
used to assess the liability of compounds for transporter-based DDIs in vivo also is 
explored. Existing challenges and approaches to examine the involvement of 
transporters in drug disposition are discussed. 
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Why a Methods Whitepaper?  
In recent years, there has been increased recognition that drug transporters, in addition 
to drug metabolizing enzymes, play an important role in the absorption, distribution, and 
excretion of many drugs (1). The importance of drug transporters has been emphasized further 
by numerous examples where loss of function of transport proteins due to polymorphisms or 
drug-drug interactions (DDIs) has resulted in clinically significant changes in drug disposition, 
efficacy and even toxicity (2).  Regulatory agencies, therefore, have come to expect that 
sponsors of new drug applications will conduct in vitro studies to assess the potential risk for 
transporter-mediated DDIs.  Although general strategies on preferred experimental in vitro 
approaches have been provided in regulatory guidance documents, little is known about the 
predictive value of most systems, or whether results obtained from various laboratories are 
comparable. 
In this whitepaper, transporter scientists from multiple pharmaceutical companies and 
academia representing the International Transporter Consortium provide an overview of the 
experimental systems currently employed to conduct in vitro transporter studies.  Advantages 
and caveats of each system are highlighted, issues concerning data interpretation are 
discussed, and general comments about how in vitro data can be used to support drug 
discovery and development programs are provided. This whitepaper focuses on the seven 
transporters identified by the International Transporter Consortium as most clinically relevant 
(1), and transporters for which there is emerging evidence of importance (3).  Where 
appropriate, discussion on other transporters has been included. Additional information about 
each of the transporters discussed in this whitepaper is detailed in the UCSF-FDA TransPortal 
(2). 
A good example of the value of an in vitro test system to predict drug disposition in vivo 
is the application of polarized cell monolayers expressing ABCB1 (MDR1 P-gp). Using such cell 
systems, various laboratories have demonstrated that a good correlation can be established 
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between the in vitro transcellular transport ratios in MDR1 or Mdr1a P-gp expressing cells and in 
vivo brain concentration ratios in Mdr1a-/-/wild-type mice (4, 5).  Another example is the 
application of cell lines transfected with OATP1B1 to qualitatively predict the potential of drug 
candidates to cause DDIs with statins (6).  However, many questions remain about the 
integration of information generated from various assays, the optimal timing of such studies in 
the drug development process, and translation of in vitro data to in vivo.  Furthermore, 
interpretation of assay results may be controversial in some cases, and assay limitations always 
must be considered.  In vitro test systems must be selected based on the characteristics of the 
compound of interest, and multiple assay systems may be needed for some transporters.  For 
instance, it is not feasible to study whether a compound with a poor apparent permeability (Papp) 
will be a substrate for an efflux transporter in a whole cell system because diffusion into the cell 
may be rate-limiting; membrane vesicle or double transfected polarized cell monolayer systems 
would be more suitable to address this question.  Likewise, biliary clearance cannot be 
assessed directly in a vesicle-based transporter assay. A goal of this whitepaper is to begin to 
address which assay systems are most appropriate to answer specific transporter questions. 
This whitepaper focuses on vesicle systems, transfected cell lines and hepatocytes because 
these presently are the most commonly used tools in transporter research in the pharmaceutical 
industry.  During our discussions, it became apparent that different approaches are used across 
laboratories and that reaching consensus was not always possible.  In such cases, we have 
presented multiple assays that could be used to address the transporter-related issues or key 
questions.    
Standardization of test systems, probe substrates and inhibitors has been implemented 
for CYP enzymes (7). This has allowed categorization of inhibitors as weak, moderate, or 
strong, which is something that currently is not available for transporters due to the lack of 
selective probe substrates and inhibitors both in vitro and in vivo.  At present, efforts to 
harmonize in vitro transporter assay formats, probe substrates and inhibitors between 
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laboratories have been very limited.  The need for investment in this area has been highlighted 
based on recent work comparing inhibition data for MDR1 P-gp across twenty-three laboratories 
with sixteen inhibitors in various expression systems (J. Bentz, H. Ellens and C. Lee, personal 
communication). The results from this comparison demonstrated a wide difference in IC50 
values, depending on the inhibitor tested.  This whitepaper provides recommendations 
regarding which systems should be used to address specific transporter-related questions in the 
drug development process.  References to standard protocols and methodological details are 
provided.  
 
Vesicle-based Transporter Assays and Uptake Studies in Recombinant Cell Lines 
  
An important point of consideration before initiating transporter experiments is which assay 
system is most appropriate.  Efflux transport of drugs and endogenous compounds from cells 
often is mediated by ATP-dependent unidirectional pumps, as exemplified by the uphill transport 
from hepatocytes into bile by the ABC transporters ABCB11 (BSEP), ABCC2 (MRP2), ABCB1 
(MDR1 P-gp) or ABCG2 (BCRP). Since these transporters are expressed in the canalicular 
(apical) membrane of the hepatocyte, intact cell systems expressing only these transporters 
may not be an appropriate system in the absence of a relevant uptake transport mechanism.  
Transport by these proteins can be studied using inside-out-oriented membrane vesicles, 
achieved by demonstration of ATP-dependent transport of a substrate into the vesicle, as 
shown originally with vesicles produced from erythrocytes (Figure 1) (8).  As there is direct 
access of the substrates to the internal side of the transporter in the plasma membrane, inside-
out membrane vesicles allow one to obtain information on substrate specificity, co-factor 
requirements, and substrate affinity.  
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Preparation of Vesicles 
Cell lines commonly used for the isolation of membrane vesicles containing recombinant 
human ABC transporters include Spodoptera frugiperda insect cells (Sf9 or Sf21) infected with a 
baculovirus containing a cDNA encoding an ABC transporter, and cDNA-transfected 
mammalian cell lines such as HeLa, V79 hamster, human embryonic kidney (HEK-293), and 
Madin-Darby canine kidney (referred to herein as MDCK although other clones including 
MDCKII are used). Endogenous background activity of ATP-dependent transport is detectable 
in all of these cell lines and requires control measurements with vesicles from non-transfected 
cells (9). Vesicles also can be isolated from tissues (e.g. kidney or liver) allowing for the 
simultaneous investigation of several endogenous ABC transporters in inside-out-oriented 
apical or basolateral membrane vesicles (10).  An important consideration in this approach is 
that cross-contamination with vesicles from the opposite membrane domain needs to be taken 
into account since different transporters in the two membrane domains may share the 
compound of interest as a substrate and have different transport capacities. 
Several groups have described the preparation of vesicles from transfected mammalian 
cells (11, 12). The most critical step for vesicle isolation is the homogenization of the starting 
material.  The method of homog nization needs to be adjusted based on the starting material, 
and it is important to keep the conditions of homogenization constant (10, 12, 13). For isolated 
cells, a very tight (small clearance between pestle and cylinder wall) homogenizer at a high 
speed and a hypotonic buffer will yield vesicles suitable for transport experiments (12). The 
strength of the homogenization may need to be balanced against the purity of the vesicle 
fraction necessary for the planned experiment. If purity of vesicles is critical, they should be 
characterized fully as described previously (10, 13),  
Because vesicles are not living cells, compounds that may be cytotoxic in other assays 
will not confound interpretation of experimental results from vesicle studies. Additionaly, vesicle 
studies are ideally suited to investigate the role of pH or pH gradients, cation and anion 
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dependency as well as driving forces for transport systems. Importantly, as vesicle transport 
experiments require rather small amounts of vesicles (e.g. 50 to 70 µg protein), it is feasible to 
conduct high-throughput assays and obtain a significantly larger number of data points in a 
short time period than from a similar amount of intact cells.  In addition, isolated membrane 
vesicles can be stored at -80oC for a long period of time and can be thawed easily for use when 
needed, although repeat freeze-thaw cycles may compromise assay performance. Now, 
membrane vesicles containing the commonly used ABC transporters are commercially 
available, allowing data comparison among different labs. 
 
 
Study Design Considerations for Vesicle-based Transporter Assays 
Co-substrate and co-factor requirements of ABC transporters should be taken into 
consideration in designing experiments. For instance, reduced glutathione, which is present in 
living cells at millimolar concentrations, is required for transport of some substrates by MRP1 
(14), MRP2 (15), and MRP4 (16); in some cases, glutathione transport was associated with 
drug transport (14, 17). Accordingly, these assays may require an additional control with 
transport in the presence of 5 mM GSH or S-methyl-glutathione. Inhibition studies for 
transporters showing cooperativity need to be performed over a range of substrate and inhibitor 
concentrations (18). It is important to realize that inhibition studies are not suitable to test 
whether or not a compound is a substrate. This approach is sometimes chosen if a new 
substrate is not available in radiolabeled form or LC-MS-MS analysis is not available. There are 
ample examples that some inhibitors are not actually transported by the carriers studied (19, 
20). 
The measured concentration of substrates and inhibitors in a vesicle suspension 
represents the unbound concentration, which is defined as the product of the unbound fraction 
and the total drug concentration.  Concentrations selected for investigation in vesicle systems 
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should bracket the expected unbound concentration at the site of transport. Unbound 
concentrations in plasma may not necessarily be equivalent to unbound cellular concentrations, 
as discussed in detail by Chu et al. (see this issue).  If albumin (or another binding protein) is 
added to the vesicle incubation buffer, as is occasionally done for poorly water-soluble 
substrates or inhibitors, the unbound concentration must be experimentally determined. Protein 
binding can be impacted by the ionic strength of the buffer, thus affecting kinetic parameters 
that depend on the unbound substrate concentration (21).  Vesicular systems are well suited to 
determine kinetic parameters for drug transport and to obtain mechanistic insight regarding 
DDIs. Further work is needed to determine whether data generated in vesicle-based systems is 
useful to predict overall drug disposition and susceptibility to DDIs when incorporated into 
pharmacokinetic models.  Modeling approaches that account for the complexity of the in vivo 
system, including the contribution of individual uptake and efflux transporters, may increase the 
overall value of data generated in vesicular systems.  
Passive permeation of substrates into the vesicles has to be taken into account. For 
ABC transporters, ATP can be replaced by 5’-AMP or by a non-hydrolyzable ATP analog such 
as AMP-PCP (see Figure 2). Additionally, binding of substrates to vesicle membranes may 
confound kinetic parameters and inhibition studies. Binding potentially can be assessed by 
performing initial uptake experiments with increasing incubation time, followed by back-
extrapolation of the initial uptake rates to zero incubation time. The intercept with the ordinate (if 
significantly different from zero) represents binding to the outer leaflet of the vesicles. Total 
binding (to the inner and outer leaflet of vesicles) can be assessed by determination of the 
osmotically sensitive intra-vesicular space for the substrate under investigation. Such 
experiments must be performed under equilibrium conditions, but with identical uptake 
conditions as used for initial uptake rates. The addition of non-specific binding proteins (e.g. 
albumin) to the ice-cold stop-solution can reduce the binding of hydrophobic substrates. If the 
binding component is large, an initial test of substrate binding to the filter is warranted. Such a 
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problem can be (in part) solved by using different filter materials or by pre-incubating filters with 
a high concentration of unlabeled substrate.  In some cases, addition of an excess of unlabeled 
substrate to the stop-solution may be useful. Filtration of the vesicles through a gel matrix by 
centrifugation may serve as another useful approach, as illustrated in Figure 1. 
Methods for quenching the transport reaction with stop-solution and filtering the vesicles 
both must be considered carefully.  In order to efficiently terminate the uptake into vesicles, 
dilution of the incubation reaction 30- to 50-fold with an ice-cold stop-buffer is required. While 
this condition is sufficient to terminate uptake of transported substrates, it does not prevent 
efflux of substrates from the vesicle lumen back into the buffer (22). Therefore, the transfer of 
the vesicle suspension into the filtration device and the filtration step must be quick, and follow a 
consistent timeline to achieve low standard deviations and reproducibility of data. 
In determining whether a compound is a substrate for an ABC transporter in vesicle 
uptake studies, it should be realized that false-negative results can be obtained for highly 
lipophilic compounds due to high non-specific binding to lipid membranes or extensive diffusion. 
For inhibition studies, selection of probe substrates is critical for the generation of meaningful 
data if a vesicular system is used to determine IC50 values. Optimal substrates should give 
significantly higher values than blanks, have a low apparent permeability, and exhibit low non-
specific binding to filters and vesicles. Ideally, probe substrates that will be selected as victim 
drugs in clinical DDI studies should be used, but this may not always be possible for technical 
reasons. In such cases, validation data need to be generated with known inhibitors to 
demonstrate that the IC50 or Ki values measured are predictive for clinical DDIs that have been 
ascribed to inhibition of the transporter of interest.  Recommended substrates and inhibitors of 
ATP-dependent transport into inside-out membrane vesicles are given in Table 1 for the 
following ABC transporters: ABCB1 (MDR1 P-gp), ABCG2 (BCRP), ABCC1 (MRP1), ABCC2 
(MRP2), ABCC3 (MRP3), ABCC4 (MRP4), and ABCB11 (BSEP). These substrates and 
inhibitors have been used successfully in the authors’ laboratories. At present, no general 
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recommendations can be provided for preferred substrates because systematic comparisons 
between laboratories have not been conducted.  
 
 
Generation of Recombinant  Cell Lines 
Full length cDNAs encoding a transporter of interest can be cloned from cDNA libraries 
using High Fidelity DNA polymerase and sequence specific primers, or in many cases can be 
obtained commercially. Native stop codons should be included in order to prevent incorporation 
of amino acids not present in the native protein. cDNAs must be sequenced for accuracy prior to 
the generation of expression systems, and mutations should be corrected by site directed 
mutagenesis. 
The host mammalian cell lines commonly used for the expression of transporters include 
Human Embryonic Kidney (HEK293) cells, Porcine Kidney Epithelial cells (LLC-PK1), Madin-
Darby Canine Kidney (MDCK) cells and Chinese Hamster Ovary (CHO) cells. Among these 
cells, HEK293 and CHO cells are used commonly for expressing uptake transporters, as they 
demonstrate low endogenous transporter activity and are easy to maintain. Several laboratories 
also use MDCK cells for the expression of uptake transporters. MDCK and LLC-PK1 cells can 
form tight polarized cell monolayers, and are used commonly for the expression of efflux 
transporters. Oocytes from Xenopus laevis have been used historically for expression cloning of 
transporters and to characterize transporter function and mechanism of transport. Although 
oocytes are an available tool, some data suggest that transporter kinetic parameters determined 
using oocytes are not always comparable to those generated in mammalian cells (23). 
Guidance from regulatory agencies indicates that transport studies should be conducted in an in 
vitro system where the human in vivo transporter function is preserved (www.fda.gov; 
www.ema.europa.eu).  
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Plasmids with transporter cDNA can be introduced into the host cell line either 
chemically, physically, or by retroviral transduction. Electroporation is a popular method for 
physical transfection and is very efficient for CHO cells. Transporter cDNA can be transiently 
transfected into the host cells, but this method is less preferred as transporter expression levels 
can be quite variable. For stable transfection, a chemical resistance gene, usually conferring 
resistance to geneticin or hygromycin, is co-constructed into the plasmid vector allowing host 
cells to constitutively produce the protein of interest under selection pressure. To improve the 
stable transfection efficiency, and to allow integration of a cDNA in a fixed locus, systems such 
as the Flp-In system have been developed, which integrates the cDNA of interest into the 
genome via Flp recombinase-mediated specific DNA recombination (24). Genetically modified 
HEK, CHO and MDCKII cells with an Flp Recombination Target (FRT) site and the matching 
expressing vector are commercially available or can be c stom made. Successful transfection 
of the transporter should be confirmed by measuring transporter mRNA, and protein production 
and localization by Western blotting and i munocytochemistry, respectively. Significant 
transport of a probe substrate and inhibition by a prototypical inhibitor (Table 2), serves as an 
indicator of the proper function of the transporter in the transfected cell line. 
   
Study Design Considerations for Uptake Studies in Recombinant Cell Lines 
For substrate determination, the compound of interest is incubated with cells expressing 
the uptake transporter, usually for <10 min unless an energy source such as glucose is 
provided. Accumulation of the compound must be significantly higher (generally more than 2-
fold) in transporter expressing than in non-transfected parental (wild-type) cells, or cells 
transfected with empty vector (mock-transfected), in order to conclude that a compound is a 
substrate. Uptake can be confirmed by comparing the uptake in the absence and presence of 
an established inhibitor (Table 2).  Prior to conducting kinetic studies, uptake should be 
conducted at various time points to determine the range of linear uptake. The recommended 
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approach for accurate determination of kinetic parameters (Vmax and Km) is described below 
(see Data Analysis). A parallel study in parental cells is recommended to determine background 
transport.  
To determine the inhibitory effect of a test compound, the intracellular accumulation of a 
probe substrate (Table 2) should be measured in the presence and absence of increasing 
concentrations of the compound of interest. Consideration should be given to the incubation 
time (pre-incubation and/or co-incubation) with the inhibitor depending on the permeability of the 
compound and whether it is a transporter substrate. In some cases, trans- or time-dependent 
inhibition could occur or the inhibitor may be metabolized. For kinetic analysis, inhibition should 
be determined at initial uptake rates of the probe substrate. The same considerations outlined 
for data obtained in membrane vesicles also apply to intact cell systems. Due to the complexity 
of transporter characteristics (e.g. overlap in substrate and inhibitor specificity across 
transporters, and the presence of multiple drug binding sites for some transporters), caution 
must be taken in extrapolating in vitro kinetic data to in vivo. 
For both uptake and inhibition studies, compound solubility should be taken into account 
in designing experiments. Organic solvents, such as DMSO, can be added to increase 
compound solubility, but the maximal concentration at which solvents are tolerated by the cell 
system (usually <1%) without impacting cell viability or transporter function should be 
determined. For compounds with low solubility, albumin or other excipients can be added to the 
incubation buffer, but the unbound concentration of the compound will need to be determined, 
as data interpretation otherwise will be complicated. 
Consistent procedures should be followed in conducting transport studies to minimize 
experimental variability, such as starting cell seeding numbers, growing period of cells and 
conditions, dosing solution preparation, and incubation time. Typically, experiments are 
conducted at 37°C.  Processing of the cells depends on the method used for compound 
detection, which may include LC-MS/MS analysis or scintillation counting.  The rate of uptake 
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commonly is normalized to protein concentration (mg) to allow accurate determination of 
transporter specific uptake compared to uptake in wild-type (or mock-transfected cells). The 
inclusion of positive and negative controls is critical for accurate interpretation of the generated 
data. . 
 
Data Analysis for Vesicle-Based Transporter Assays and Uptake Studies in Recombinant 
Cell Lines 
The general rules outlined below apply both to transport experiments with cellular 
systems and to transport experiments with vesicles.  The time course of uptake may deviate 
quickly from linearity due to rapid accumulation of substrate inside vesicles or cell lines.  
Therefore, selection of early and appropriate time points in the initial linear phase (i.e. initial 
uptake rates) is critical for accurate determination of kinetic parameters. For example, the ATP-
dependent transport of the glutathione S-conjugate LTC4 into MRP1-containing membrane 
vesicles is shown in Figure 2.  Linearity of the system with respect to protein amount or cell 
number also needs to be considered in the experimental design, and binding to the membrane 
should be taken into account. In the case of vesicles, the rate of ATP-dependent transport of 
various substrates is calculated on the basis of vesicle protein (e.g. given in mg) and yields only 
relative values for different substrates within a membrane preparation. Absolute values are 
obtained for affinity (Km value) and inhibition constants (Ki and IC50 values), and are not affected 
by the percentage of inside-out-vesicles, assuming that transport is ATP-dependent. To best 
define the kinetic parameters, a zero concentration control (blank) and at least seven substrate 
concentrations should be selected that cover the linear and non-linear range of transport; the 
highest concentration evaluated should be at least 90% of the maximal transport velocity (e.g. 
Vmax). The standard procedure for data analysis is to fit a Michaelis-Menten equation (Table 3, 
eq. 1) to the data. A linear component can be added to the Michaelis-Menten equation to 
account for passive diffusion, if applicable (Table 3, eq. 1). Non-linear regression analysis of the 
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non-transformed data is the preferred method of data analysis, although linear transformation of 
data can help identify the involvement of multiple transporters or multiple binding sites.  For 
example, Eadie-Hofstee or Hanes-Woolf plots readily provide information on the presence and 
activity of more than one transporter. The use of Hanes-Woolf or Hill plots should be considered 
when complex transporter biology (e.g., cooperativity) is suggested (18). Assessment of drug 
interaction potential often involves determination of IC50 values using a probe substrate at a 
concentration well below the Km and a range of purported inhibitor concentrations relevant to 
expected or known clinical exposures, with consideration for total and unbound maximal 
concentrations at the relevant site(s) of inhibition (e.g., plasma, intracellular). Important 
considerations in the determination of IC50 values include:  
(i) The IC50 value depends on the substrate concentration (in contrast to the Ki value, which 
gives the affinity of the inhibitor to the probe substrate binding site). This is relevant if 
IC50 values are used for in vivo extrapolations.  
(ii) IC50 values will approach Ki if a substrate concentration far below the Km is used (see 
points (iv) and (v) below). 
(iii) Different mathematical models may be used to estimate IC50 values, which may affect 
the comparison of IC50 values between laboratories.  
(iv) IC50 values do not provide information on the type of inhibition.  
(v) Study designs should utilize probe substrate concentrations within 2-fold of the Km value. 
If the substrate concentration is >50% of the Km value, calculation of Ki values with the 
Cheng-Prusoff equation (Table 3, eq. 2) may yield incorrect estimates of the true 
value. (At low probe substrate concentrations, the accuracy of the data will be affected 
strongly by binding problems). 
(vi) The Cheng-Prusoff equation assumes that the inhibition is competitive in nature.  
Dixon plot analysis is the method of choice for detailed analysis of inhibition data including 
determination of the Ki value; this approach provides information on the type of inhibition 
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(competitive versus non- or uncompetitive). The Ki value is a more robust parameter that should 
be comparable across laboratories for a given set of inhibition data.  The use of proper controls 
and validated assays coupled with IC50 value determination may be acceptable to guide 
decision making with regard to DDI potential. Similar considerations also apply to the analysis of 
cell-based systems expressing uptake transporters. 
 
Cell-based Transporter Assays 
Bidirectional Transport in Recombinant Cell Lines 
Bidirectional transport assays in polarized cell monolayers (e.g. LLC-PK1, MDCK or 
Caco-2) are used to study efflux transporters or the interplay between uptake and efflux 
transporters (Figure 3.A). Assays are performed with cell lines stably or transiently transfected 
with cDNAs encoding the transporter(s) of interest, as discussed above, and cells are seeded 
on a permeable membrane support to form a tight cell monolayer. In most cell lines established 
thus far, uptake transporters are localized in the basolateral membrane (e.g., OATP1B1, 
OATP1B3, OATP2B1, OCT1, or OCT2), and efflux transporters in the apical membrane (e.g., 
MDR1 P-gp, BCRP, MRP2, or MATE; (25-27)). 
 In a typical bidirectional transport experiment to establish transporter-mediated 
uptake/efflux, the test compound is added to the apical (A) compartment, with buffer in the 
basolateral (B) compartment (A-B transport), and in parallel wells, test compound is added to 
the basolateral compartment, with buffer in the apical compartment (B-A transport). Acceptance 
criteria for the tightness of the cell monolayer need to be established. Typically, this is assessed 
by measuring the paracellular flux of a low permeability compound (e.g. inulin, mannitol, or 
lucifer yellow). Experiments can be conducted as a time course by taking samples from both 
compartments at various time points, but in most cases transport is linear over time, and 
therefore, samples can be taken at one fixed time point (typically at t = 1-4 hr (28)). For each 
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direction of transport, the apparent permeability (Papp) is calculated (Table 3, eq. 3), and data 
are reported as the Papp B-A/A-B ratio.  
Theoretically, the B-A/A-B in the control cell line will be at unity, but this is not always the 
case due to the presence of endogenous transporter activity (29, 30). The cut-off for significant 
transport (with no transport in the control cell monolayers) is typically at a B-A/A-B ratio of 2, but 
depends on the sensitivity and reproducibility of the assay system. Accuracy of the transport 
ratio also depends on the mass balance, which is defined as the total drug recovered in the 
receiver and donor solutions at the end of the experiment relative to the amount of drug added 
at t = 0. Mass balance is important to consider for compounds with low solubility, high non-
specific binding, or possible metabolism. In such cases, the assay will yield data that are difficult 
to interpret. A typical cut-off for mass balance is >70%. 
 Bidirectional transport assays are a sensitive method to determine transport of test 
compounds because only transport of compound that is fluxed through the cell monolayer 
(either para- or trans-cellularly) is measured and therefore, transport measurements are less 
confounded by compound binding to cell membranes (as in direct cell uptake or vesicular 
uptake experiments). However, there are limitations to this system: (i) Compounds can be 
identified as non-substrates due to saturation of efflux transport activity. Based on experience in 
multiple drug discovery programs, this usually can be avoided for MDR1 P-gp by choosing drug 
concentrations ≤1 µM (RE, unpublished data). (ii) For cells expressing only apical efflux 
transporters, transport will be limited by the diffusion rate across the basolateral membrane or 
be dependent on the presence of endogenous uptake transporter(s). Thus, for compounds with 
low permeability, the Papp B-A/A-B ratio may be underestimated. In cases where a compound 
is known to be a substrate for an uptake transporter, this problem can be overcome by the 
application of double transfected cell lines. (iii) Quantitative interpretation of data obtained is 
difficult, although correlating B-A/A-B ratios to the capacity of test compounds to cross the 
blood-brain-barrier has been successful (4, 5). Recent studies have suggested that endogenous 
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transporters present in polarized cell monolayers may complicate determination of kinetic 
parameters (e.g., deriving transport kinetics via P-gp in MDCK cells). Various complex modeling 
approaches to derive kinetic data based on bidirectional transport experiments have been 
published and are discussed by Zamek-Gliszczynski et al. (see this issue). 
 For known MDR1 P-gp substrates, bidirectional transport assays are one of the 
recommended methods to assess inhibition of transport by potential perpetrator drugs (1). In 
these experiments, cell monolayers are incubated with various concentrations of test compound 
in both the apical and basolateral compartment, and the effect on the bidirectional transport of a 
probe substrate is measured. If studies are conducted to assess the propensity of a test 
compound to be a perpetrator of MDR1 P-gp in the clinic, use a clinically relevant drug as the 
substrate is recommended because MDR1 P-gp is known to contain multiple drug binding sites 
(31), and inhibition may be substrate dependent. IC50 values can be calculated by various 
methods, but currently there is no consensus on the most optimal approach (32, 33).  An 
extensive evaluation of IC50 values across a range of laboratories with various P-gp inhibitors 
and digoxin as the probe substrate has revealed high inter-lab variability, even if cell lines from 
the same origin and identical IC50 calculation methods were employed (J. Bentz, H. Ellens and 
C. Lee, personal communication). Thus, it is recommended that assay systems are validated 
within each lab with a range of known MDR1 P-gp inhibitors.    
Caco-2 cell monolayers can be used as an in vitro screening tool to predict oral 
absorption in humans as Caco-2 cells are derived from human colon carcinoma and resemble 
the characteristics of human small intestinal enterocytes when grown on permeable filters, form 
tight junctions, microvilli, and produce several human enzymes and transporters (34). 
Conducting experiments with Caco-2 cells is similar to other bidirectional transport assays. A 
detailed description of cell culture, experimental procedures and data analysis can be found in 
Hubatsch et al. (35). A correlation has been established using Caco-2 cells between trans-
cellular and para-cellular flux for a number of drugs, and transporter-mediated drug absorption 
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(36).  Limitations of Caco-2 assays include the long differentiation time, and the 
significant variability in permeability and transporter expression levels among laboratories. 
Thus, markers for permeability (e.g., inulin and propanolol) should be included as controls in 
each experiment, and the expression levels of transporters should be determined by each 
individual laboratory. Of note, it has been established that MDCK monolayers also can be used 
as model systems to predict oral absorption of drugs for non-transporter substrates (37, 38).   
 
Suspended Hepatocytes to Characterize Hepatic Uptake   
Freshly isolated or cryopreserved hepatocytes have been widely accepted as a holistic 
model to identify substrates for hepatic uptake transporters and to predict hepatic clearance.  
Fresh hepatocytes traditionally are isolated by collagenase perfusion of livers from rat or human 
donors as described previously (39). The hepatocyte suspension is prepared in medium (e.g., 
William’s E medium) or buffer (e.g., Hanks Balanced Salt Solution) without phenol red, and 
aliquots of hepatocytes are then dispensed into a test tube and kept on ice until the start of the 
experiment. Suspended hepatocytes shoul  be used within a few hours because cell viability 
decreases over time.  After a 10-minute pre-incubation at 37oC, active uptake is initiated by the 
addition of an equal volume of medium or buffer containing test compounds with and without 
known transporter inhibitors. At designated time points, the incubation is terminated by rapidly 
separating the cells from the medium or buffer using a rapid filtration approach with a cell 
harvester, direct centrifugation, or centrifugation through a layer of mineral oil (6, 40).  [14C]Inulin 
can be used to correct for adherent fluid volume. The cells are lysed and subjected to analysis 
by LC-MS/MS or scintillation counting.  Active hepatic uptake is estimated from the initial uptake 
phase (Table 3, eq. 4), which may occur as quickly as 0.5 min (e.g. taurocholate has rapid 
uptake 0.5 to 1.5 minutes). Initial rates of hepatic uptake are estimated by linear or dynamic 
regression analysis (41).  Uptake measured beyond the initial range may be confounded by 
both uptake and efflux processes (30). The percentage of active uptake can be determined from 
Ac
ce
pte
d m
an
us
cri
pt
ACCEPTED ARTICLE PREVIEW 
© 2013 American Society for Clinical Pharmacology and Therapeutics. All rights reserved 
the slope of the initial uptake phase compared to the slope of uptake with known inhibitors, 
intended to represent only the passive component of uptake (Table 3, eq. 5).  There is some 
debate among experts about the best approach to assess the contribution of passive diffusion to 
overall uptake.  The classic method involved measurement of uptake in suspended hepatocytes 
at 4oC (40), but this approach is confounded by the fact that membrane fluidity is also 
temperature sensitive. Uptake by the sodium-dependent taurocholate co-transporting 
polypeptide (NTCP) can be determined using an uptake buffer with and without sodium (NaCl 
and NaHCO3 replaced with choline Cl and choline bicarbonate, respectively) (42). Replacing 
extracellular NaCl with KCl for these studies may alter cell homeostasis, impair cell viability, and 
should be avoided (43). To reduce the labor associated with the isolation of fresh hepatocytes, 
cells also can be cryopreserved if they are not used immediately post isolation because the 
majority of hepatic drug transporters appear to be preserved (44). Suspended hepatocytes often 
are used to determine the role of transporters in hepatic uptake because plated hepatocytes 
exhibit decreased transporter function after just a few hours in culture (45). Inter-individual 
differences in protein expression and/or genetic polymorphisms can be overcome by pooling 
hepatocytes from multiple donors (46, 47). 
Hepatocyte uptake studi s are useful to assess the contribution of passive vs. active 
processes to initial uptake in the species of interest. Data may be confounded by efflux from 
hepatoyctes if studies are not conducted within the linear range of initial uptake.  Nonspecific 
binding of some compounds may be significant and must be accounted for during data analysis.  
Due to the lack of specific inhibitors and substrates, it may be challenging to determine which 
individual isoforms of specific uptake transporters are involved in uptake of compounds. 
Suspended hepatocytes are not suitable for measuring canalicular efflux because proteins on 
the canalicular membrane internalize during hepatocyte isolation (48).   Recently, it was found 
that in cryopreserved hepatocytes the passive permeability of the OATP substrate pitavastatin 
varied significantly among donors although the absolute amount of OATP protein was relatively 
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constant; membrane leakage may contribute to this observation, which would complicate the 
interpretation of uptake data (49).  Further investigations are needed to confirm whether this 
finding applies to other substrates when cryopreserved hepatocytes are used for uptake studies. 
As an alternative to measuring compound uptake, compound disappearance from the medium 
has been proposed as a substitute for measuring direct uptake (50).  However, this method 
does not allow discrimination between adsorption of compound to incubation plates or uptake 
into cells, and precludes kinetic analysis of the data (an important assumption of the Michaelis-
Menten equation is that concentrations are constant over the time interval of measurement).  
 
Sandwich-Cultured Hepatocytes (SCH) to Characterize Hepatic Uptake and Biliary 
Excretion 
The use of sandwich-cultured hepatocytes (SCH), as shown in Figure 3B, has become a 
valuable in vitro tool in drug discovery and development.  SCH retain more in vivo-like 
properties, including the formation of intact canalicular networks and polarized excretory 
function (51) .  This system has been established successfully for multiple species including rat 
and human hepatocytes. Freshly isolated or cryopreserved hepatocytes are cultured on 
collagen coated plates overlaid with collagen or MatrigelTM (BD Bioscience) for a period of 4 
days (rat SCH) or 6-7 days (human SCH), depending on the species and culture conditions, to 
allow time for hepatocyte polarization and re-establishment of canalicular networks.  Hepatic 
uptake in SCH is initiated by the addition of HBSS containing substrates, with or without 
inhibitor. The hepatic uptake of test compounds is estimated from the initial uptake phase 
(typically less than 2 min); the initial uptake rate in SCH is estimated by linear or dynamic 
regression. The uptake clearance (Cluptake) is calculated according to Table 3, Eq. 4.  (52).  
Incubating SCH in calcium/magnesium-free buffer disrupts the tight junctions that form the bile 
canalicular network (53). Using this approach, the biliary excretion of compounds can be 
determined by comparison of accumulation in normal buffer (representing cell + bile canalicular 
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network content) vs. accumulation in calcium/magnesium-free buffer (representing cellular 
accumulation) (B-CLEAR® technology) (53, 54). Data are corrected for any nonspecific binding 
of compound to the collagen or MatrigelTM plates.  
The biliary excretion index (BEI), which represents the fraction of accumulated 
compound that resides in the bile compartments, is calculated based on the Accumulation(std, 
HBSS) and Accumulation(Ca2+/Mg2+, free), which represents the cumulative amount of compound in 
SCH in the presence and absence of Ca2+/Mg2+, respectively (Table 3, Eq. 6) (53). The 
apparent in vitro biliary clearance (CLbile,app) is calculated based on the medium AUC, and 
defines the apparent biliary excretion clearance from medium to bile (Table 3, Eq. 7) (53). The 
CLbile,app and BEI typically are determined at 10 min, but the optimal time is compound-specific, 
which depends on the time-course of accumulation in hepatocytes. Intracellular concentrations 
can be estimated from the mass of compound that accum lates in hepatocytes normalized for 
hepatocyte volume (55), or by using Kp,uu obtained from a model where active uptake processes 
are involved (Chu et al., see this issue). The intrinsic biliary efflux clearance (CLbile,int), which 
represents the biliary efflux clearance from hepatocyte to bile, can be calculated based on the 
intracellular AUC (Table 3, Eq. 8). 
The BEI obtained from SCH is a qualitative index of biliary excretion (56).  BEI and 
biliary clearance values should be compared to a positive control, such as the model bile acid 
taurocholate, which undergoes rapid hepatic uptake and extensive biliary excretion.  Hepatic 
uptake and biliary clearance values can be scaled to per kilogram of body weight, depending on 
the species, and used as input for PBPK models to predict the pharmacokinetics of test 
compounds (57, 58).  In vitro biliary clearance values generated for compounds in SCH and 
scaled biliary clearance values correlate well with in vivo biliary clearance data in rats (53, 59, 
60) and humans (61, 62).   
A caveat of the SCH system is that maintaining cells in Ca2+-free medium for prolonged 
periods of time (>20-30 min) causes cell toxicity (51). Thus, compounds with a low transport 
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clearance require a modified experimental design to accurately estimate cellular accumulation 
and biliary excretion.  The maintenance of metabolizing enzymes and transporter expression in 
human SCH is dependent on culture conditions and has been characterized (51).  Inducers and 
inhibitors can be employed to assess DDI potential of drugs and generated metabolites in SCH, 
which contain functional trafficking and regulatory machinery along with hepatocyte-specific 
endogenous compounds (51, 63).  Modifications of the SCH system that attempt to more closely 
mimic the in vivo architecture (e.g., co-cultures, scaffolds and other extracellular matrices, 
microfluidic devices) continue to be explored. Whether these more sophisticated models will 
provide significant advantages to transporter scientists selecting the optimal model from their 
drug development toolkit remains to be determined.  
 
Integration of In Vitro Transporter Data 
Selection of appropriate in vitro tool(s) to investigate the role of transporters in 
compound disposition depends on the scientific hypotheses that need to be addressed.  Table 4 
summarizes strengths and weaknesses of the various in vitro transporter assay systems.  Table 
5 outlines several potential in vitro strategies to address specific questions that may arise during 
drug discovery and development related to the role of transporters in absorption, distribution, 
clearance, and drug interactions; alternate model systems and/or approaches are included.  
Typically, these questions originate from preclinical in vivo findings, clinical observations and/or 
prior knowledge about the disposition of compounds with similar chemical structures. For 
example, if the systemic exposure of a compound following oral administration does not 
increase proportionately with increasing dose in preclinical studies, questions about possible 
involvement of transporters in drug absorption may arise. Appropriate in vitro strategies, guided 
by physicochemical properties (64) or data generated from in silico modeling, can be applied to 
assess the role of transporters in active uptake and/or apical efflux.  Although the results may 
support involvement of a transporter mechanism relevant to a particular preclinical species, 
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extrapolation between species often is not possible due to species differences in substrate 
specificity, transporter expression, and/or absolute protein levels. 
An in vitro experimental strategy may involve multiple steps using different model 
systems, requiring stepwise or parallel integration of the information generated.  This approach 
extends beyond the questions of whether or not a compound is a substrate or inhibitor of a 
specific transporter.  Such questions can be addressed using well-validated model systems, as 
described earlier and outlined in Table 4.  The ultimate goal of an experimental strategy is to 
integrate all available experimental transporter data to better understand drug disposition and 
predict the propensity for transporter-mediated drug interactions in humans.  
With the availability of many transporter assays and assay formats, a vast amount of 
data can be generated for compounds during the development process.  Often, different 
experimental approaches can be applied to address the same scientific question as long as the 
experiments are designed appropriately, the assumptions about each experimental system and 
the behavior of the compound in each syste  are correct, and the limitations have been 
considered.  A formidable challenge with the availability of multiple in vitro assays is determining 
the in vivo relevance of information generated, and specifically how transporter data can be 
translated to the clinical situation.  Generation of transporter data should not be viewed simply 
as a “box-checking” exercise during the drug development process. Instead, factors such as 
therapeutic indication, possible co-medications in the target patient population, and therapeutic 
index should be taken into account. Developing a drug transporter assessment strategy, 
including the timing and selection of transporters to be investigated, is an important part of the 
development plan, as discussed in detail by Tweedie et al. (see this issue).   
The role of transporters in the disposition of a compound can be assessed from either a 
“bottom up” or “top down” approach.  In the former, information on transporters is obtained prior 
to clinical studies and these results are scaled or modeled to gain insight into the clinical 
relevance of this information.  The “top down” approach relies first on the generation of clinical 
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data, and subsequent assessment of transporter involvement to explain clinical findings and 
define a plan for further clinical development. The risk with the “bottom up” approach is the 
possibility that data generated are not relevant or are difficult to interpret.  In contrast, the “top 
down” approach may reveal critical transporter issues in advanced stages of drug development 
that no longer can be mitigated, rather only managed through the final development process.  
The optimal approach customizes the transporter assessment strategy based on project-specific 
needs, uses translatable in vivo and in vitro models, and integrates knowledge (e.g., preclinical 
data, physicochemical properties, in silico modeling, and/or frequently co-administered drugs) to 
drive the need for information about the involvement of transporter(s), and the relative 
contribution of individual transporters in disposition of the compound. If transport proteins are 
involved in absorption, clearance and/or distribution of the compound, then follow-up studies to 
assess a DDI liability would be necessary as discussed in the FDA and EMA guidance 
documents 
(http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/U
CM292362.pdf; www.ema.europa.eu). If no interactions with the compound and multiple 
transporter probe substrates or inhibitors are observed, then the potential for transporter-based 
DDIs will be low, and further studies may not be necessary or could be delayed to a later stage 
of development.  If an interaction is observed, further studies will be necessary to identify the 
transporter(s) involved in the uptake or efflux of the compound and its metabolites under 
evaluation using information from multiple transporter probe substrates and inhibitors in whole 
cell systems, membrane vesicles and/or transport assays utilizing recombinant systems. This 
approach may provide a practical “real world” evaluation of the compound by first determining if 
a potential problem exists, and secondly providing direction to evaluate the involvement of 
specific uptake and/or efflux transporters. 
Knowledge regarding unbound drug concentrations at the relevant sites may aid in 
determining the clinical relevance of in vitro data. As drug transporter science evolves, an 
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understanding of disease state alterations in transporters (e.g., altered hepatic transporters in 
cholestasis (65), and non-alcoholic steatohepatitis (66)), and elucidation of complex 
mechanisms of drug-transporter interactions other than competitive inhibition (e.g., time-
dependent inhibition of hepatic uptake by cyclosporine A (67)) may help translate in vitro data to 
the clinical situation. In vitro DDI studies should be designed to elucidate the potential role of the 
compound as a “victim” and/or “perpetrator”, preferably with clinically relevant transporter probe 
substrates or inhibitors, and incorporation of relevant positive controls (Tables 1 and 2).  More 
dedicated clinical studies are needed to evaluate the sensitivity of “clinically relevant probes” 
currently listed in Table 2 for a given transporter. 
Careful consideration is needed when integrating transporter data from several 
experimental systems. Many compounds are transported by more than one uptake or efflux 
protein and also may be metabolized in vivo.  Since analyses in membrane vesicles or 
transfected cell lines usually only takes into account a single transporter of interest, differences 
in results compared to data generated in intact primary cells may be attributed to compound 
transport by alternate mechanisms present in these more complex systems.  Such transporter 
multiplicity becomes especially important when assessing the clinical relevance of drug 
interactions of victim drugs that may have competing clearance mechanisms.  Cell lines also 
lack relevant drug metabolizing enzymes that may impact the overall disposition of a compound.  
Primary cells such as hepatocytes represent a more holistic in-vivo system capable of 
expressing many of the relevant drug transporters and drug metabolizing enzymes in culture, 
and theoretically should be helpful in establishing the rate-determining step in drug elimination. 
When considering the integration of in vitro results with in vivo observations, one must also 
consider transporter differences across species (68), the impact of protein binding on unbound 
drug available to interact with transporters, and blood flow that may be rate-limiting in delivery of 
a compound to the site of transport.    
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Despite each individual system’s limitations, data from these models can be integrated 
effectively to gain insight concerning transporter-related ADME questions.  For example, 
hepatocytes in suspension in conjunction with transfected cell lines are valuable to assess the 
relative role of OATPs in the uptake of drug substrates. These combined data can be more 
quantitative in the estimation of DDI risk than studies with transfected cell lines alone (69).  SCH 
are a useful approach to assess overall biliary excretion of a compound to identify transporter 
involvement.  Coupling these data with information generated in vesicles from cell lines 
overexpressing the transporter of interest can help define the actual mechanism(s) of 
canalicular excretion.  Although the role of transporters in toxicity is still emerging, transport 
mechanisms have been implicated as possible causes for elevated serum bile acids 
(cholestasis), and elevated conjugated bilirubin (conjugated hyperbilirubinemia).  For example, 
BSEP inhibition has been attributed to an increase in the risk for cholestatic drug-induced liver 
injury (70, 71).  However, many compounds that inhibit BSEP do not cause cholestasis.  
Integration of inhibition data from BSEP-expressing membrane vesicles with SCH data, where 
intracellular concentrations of parent compound and potential metabolites can be assessed, and 
the impact on BSEP and other hepatic bile acid uptake and efflux transporters can be 
examined, may better predict th  ultimate clinical impact of drug-induced transporter-mediated 
alterations in bile acid disposition (55).  In the case where hyperbilirubinemia (in particular the 
conjugated species) is observed clinically with a lead compound, OATP-overexpressing cell 
lines, hepatocyte uptake and inhibition studies, MRP2 vesicle inhibition assays, and assessment 
of UGT1A1 inhibition may be useful in assessing potential clinical liabilities of closely related 
backup compounds being considered for development.  A complementary, integrative approach 
is to use human SCH to characterize the effects of a compound (and generated metabolites) on 
the hepatobiliary disposition of bilirubin and its glucuronide conjugates (72). 
Recently, efforts have been initiated to incorporate data from different in vitro models   
into translational pharmacokinetic models, including PBPK models (Zamek-Gliszczynski et al., 
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see this issue) to maximize interpretation of the data, explain in vivo findings, and predict 
transporter-mediated alterations in pharmacokinetics/pharmacodynamics and drug interactions 
(58, 73). The complexity of biological systems coupled with the multitude of factors that 
influence the ultimate endpoints of drug efficacy and toxicity in patients, highlights the necessity 
of comprehensive modeling and simulation approaches to understand and predict transporter-
mediated changes in drug disposition in humans. 
The development and use of in vitro transporter assays has greatly advanced our 
understanding of the role that transport mechanisms can play in drug disposition and drug 
interactions. The abundance of available in vitro tools has enabled the testing of transporter-
related hypotheses in complementary assays, often allowing for enhanced understanding of 
how transporters interact with novel chemical entities.  Although the emergence of tools has 
facilitated easier assessment of transporter function, the availability of many different transporter 
assays has emphasized the need for additional research.  The use of validated, standardized 
probe substrates and inhibitors with the requisite specificity for transporter mechanisms is 
critical in interpreting transporter assay data.  Examples of in vitro correlations of transporter 
data with in vivo clinical data have emerged, but continued efforts are needed to establish 
validation criteria for transporter assays and to better define the utility of probe substrates and 
inhibitors in clinical DDI studies. 
 
Outlook 
The field of drug transport continues to evolve at an accelerated pace.  Integration of in 
vitro transporter data into modeling approaches such as physiologically-based PK/PD modeling 
should further improve the quantitative prediction of the effect of transporters on drug 
absorption, disposition, and DDIs.  A sound strategy for the evaluation of drug transporters will 
rely on the integration of multiple transporter assays to translate specific mechanisms of 
transport to overall in vivo disposition.  As novel transporter assays continue to be developed 
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and existing assays are refined to better mimic the in vivo setting, the paradigms for in vitro and 
in vivo transporter evaluation will evolve in parallel to better predict the clinical impact of these 
mechanisms on safe, effective therapies for patients. 
 
 
Figure legends 
Figure 1. Scheme for transport assays for ATP-dependent efflux pumps. After isolation of 
plasma membranes from ABC transporter-expressing cells, a mixture of inside-out and right-
side-out membrane vesicles can be formed. Only the inside-out-oriented vesicle fraction reacts 
with ATP to transport substrates into the vesicle, while 5’-AMP serves as a negative control. 
Vesicles containing the substrates can be isolated on filter membranes in the case of most 
transport substrates, however, for very hydrophobic substrates, which bind strongly to the filter 
membranes, centrifugation through a small gel matrix column may be preferable (12, 13, 74). 
Detection of intra-vesicular substrates may be based on radioactivity, fluorescence, LC/MS, or 
LC/MS/MS. 
 
Figure 2. ATP-dependent transport of 3H-labeled leukotriene C4 (50 nM) into plasma membrane 
vesicles containing ABCC1 (MRP1). Transport in the presence of 4 mM ATP or 4 mM 5'-AMP is 
shown in the left panel; net ATP-dependent transport on the right. The quinoline-based LTD4 
receptor antagonist MK-0571 (5 µM) is a potent inhibitor of MRP1-mediated transport (12). 
Reproduced with permission from Methods in Enzymology 292:613, 1998. 
 
Figure 3.  Schematic representation of transport through polarized cell monolayers (Panel A), 
and transport studies in sandwich-cultured hepatocytes (Panel B). 
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Table 1.  Recommended Probe Substrates and Inhibitors for Human ATP-dependent Transport into Membrane Vesicles 
 
 
Transporter Assay Substrates Inhibitors 
ABCB1 (MDR1 P-gp) [3H]-N-methyl-quinidine (1) 
 
GF120918 (2) 
Cyclosporin A 
PSC833 
ABCG2 (BCRP) Mitoxantrone (2), 
[3H]-Methotrexate (3) 
Estrone 3-Sulfate 
Ko143 (2) 
GF120918 (4) 
 
ABCC1 (MRP1) [3H]-Leukotriene C4 (5, 6), 
[3H]-Estradiol 17ß-glucuronide (5) 
[14C]-Ethacrynyl glutathione (7) 
MK-571 (5) 
ABCC2 (MRP2) [3H]-Leukotriene C4 (5), 
[3H]-Estradiol 17ß-glucuronide (2) 
[14C]-Ethacrynyl glutathione (8) 
Carboxy-dichlorofluorescein (9, 10) 
MK-571 (5) 
 
ABCC3 (MRP3) [3H]-Estradiol 17ß-glucuronide (11)  
Carboxy-dichlorofluorescein (9) 
Bromosulfophthalein 
MK-571 
ABCC4 (MRP4) [3H]-Leukotriene C4 (12) 
[3H]-Dehydroepiandrosterone 3-sulfate (DHEAS) (13) 
[3H]-Folate (14) 
MK-571 (5) 
 
ABCB11 (BSEP) [3H]-Taurocholate (cholyltaurine) (10) Cyclosporin A (10) 
PSC-833 
 References listed in this table are located in supplementary material available online. 
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Table 2.  Recommended Transporter Probe Substrates and Inhibitors Commonly Used in Single Transfected Cell Systems 
or Caco-2 Cells, and Potential Clinical Probes 
 
Transporter Recommended In 
Vitro System(s) 
Positive Control Substrates Inhibitors Potential 
Therapeutic 
Drug 
Substrates 
ABCB1 (MDR1 P-gp)a LLC-MDR1 
MDCK-MDR1 
Caco-2 
Digoxin (15) 
Verapamil (16) 
Talinolol (17) 
Amprenavir (18) 
GF120918 (19)  
Ketoconazole (19) 
Verapamil (19) 
Cyclosporin A (19) 
PSC833 (20) 
Digoxin 
ABCG2 (BCRP) MDCK-BCRP 
Caco-2 
Prazosin (21) 
Sulfasalazine (Caco-2) (22) 
Cimetidine (23) 
Ko143 (24) 
GF120918 (4) 
 
Rosuvastatin 
Methotrexate 
 
ABCC2 (MRP2)a MDCK-MRP2 Vinblastine (8) 
Paclitaxel/Docetaxel (25) 
MK-571 (26) 
Probenecid (27) 
Cyclosporin A (28) 
PSC833(29, 30) 
Vinblastine 
Cyclosporin A 
 
OCT1a (SLC22A1) CHO-OCT1 
HEK293-OCT1 
Tetraethyl ammonium (31) 
1-methyl-4-phenylpyridinium (31) 
Metformin (31) 
Decynium-22 (31) 
Quinidine (31) 
Verapamil (31) 
Metformin 
Lamivudine 
OCT2a (SLC22A2) CHO-OCT2 
HEK293-OCT2 
Tetraethyl ammonium (31) 
Metformin (31) 
Decynium-22 (31) Metformin 
Lamivudine 
OAT1 (SLC22A6) CHO-OAT1 
HEK293-OAT1 
MDCK-OAT1 
p-Aminohi purate (31) 
Cidofovir (31) 
Methotrexate (32) 
Probenecid  (33) Cidofovir 
Cephradine 
Ciprofloxacin 
OAT3 (SLC22A8) CHO-OAT3 
HEK293-OAT3 
MDCK-OAT3 
Estrone 3-sulfate  (31) 
Cimetidine (31) 
Methotrexate (32) 
Probenecid  (33) Cimetidine 
Cephradine 
Ciprofloxacin 
OATP1B1a 
(SLCO1B1) 
CHO-OATP1B1* 
HEK293-OATP1B1* 
MDCK-OATP1B1* 
Bromosulfophthalein (34) 
Estradiol 17ß-glucuronide (35) 
Estrone 3- sulfate (36) 
Pitavastatin (36) 
Atorvastatin (36) 
Pravastatin (36) 
Rosuvastatin (30) 
Valsartan (37) 
Estropipate (38) 
Cyclosporin A (39) 
Rifampin (40) 
Rifamycin SV (40) 
Bromosulfophthalein (41) 
Rosuvastatin 
Atorvastatin 
Pitavastatin 
Pravastatin 
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OATP1B3 a 
(SLCO1B3) 
CHO-OATP1B3* 
HEK293-OATP1B3* 
MDCK-OATP1B3* 
Cholecystokinin octapeptide (36) 
Estradiol 17ß-glucuronide (42) 
Bromosulfophthalein (36) 
Valsartan (36) 
Bromosulfophthalein (43) 
Ursolic acid (38) 
Cyclosporin A (39) 
Rifampin (40) 
Rifamycin SV (40) 
Telmisartan 
OATP2B1 a 
(SLCO2B1) 
CHO-OATP2B1* 
HEK293-OATP2B1* 
MDCK-OATP2B1* 
Estrone 3-sulfate (36) Bromosulfophthalein (43) Rosuvastatin 
MATE-1 (SLC47A1) CHO-MATE1 
HEK293-MATE1 
Tetraethyl ammonium (44)  
1-methyl-4-phenylpyridinium (44) 
Metformin (44) 
Quinidine (44) 
Verapamil (44) 
Cimetidine (45) 
Pyrimethamine (44) 
Metformin 
MATE-2, MATE-2K 
(SLC47A2) 
CHO-MATE-2K 
HEK293-MATE2K 
Tetraethyl ammonium (44) 
1-methyl-4-phenylpyridinium (44) 
Metformin (44) 
Quinidine (44) 
Verapamil (44) 
Cimetidine (45) 
Pyrimethamine (44) 
Metformin 
a
 Note effects of multiple binding sites. Probe-dependent IC50/Ki values have been described. *Boosting expression by treating cells 
with butyrate (10 mM, 24 hrs) is needed for several of the commonly used expression systems (46); References listed in this table 
are located in supplementary material available online. 
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Table 3.  Commonly Used Equations for Calculation of Kinetic Parameters in Vesicles, Cell Lines, and Hepatocytes. 
Equation Application Reference 
in Text 
 
Determination of kinetic 
parameters to describe 
saturable active transport 
and passive diffusion 
Eq. 1 
 
Conversion of IC50 to 
absolute inhibition constant 
for competitive inhibitors 
Eq. 2 
Determination of apparent 
permeability in Transwell® 
systems 
Eq. 3 
 
Determination of uptake 
clearance in cells or 
vesicles 
Eq. 4 
 
Determination of active vs. 
passive uptake in cells or 
vesicles 
Eq. 5 
 
Calculation of in vitro biliary 
excretion index in SCH 
Eq. 6 
 
Calculation of apparent in 
vitro biliary clearance in 
SCH 
Eq. 7 
 
Calculation of intrinsic in 
vitro biliary clearance in 
SCH 
Eq. 8 
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∆ (delta): change over time; Accumulation(T2) and Accumulation(T1) represent the cumulative amount of drug in SCH over the period 
T1 to T2.  Accumulation(Std,HBSS) and Accumulation(Ca2+/Mg2+, free) represent the cumulative amount of compound in SCH in the presence 
and absence of Ca2+/Mg2+, respectively.  Clbile,app: apparent biliary clearance from medium to bile; Clbile,int: intrinsic biliary clearance 
from cell to bile.  The area under the curve (AUC) in the medium can be calculated based on the medium concentrations of 
compound at the beginning and end of the accumulation period, or assumed equivalent to the product of the incubation time and the 
initial medium concentration.  AUCcell can be estimated from intracellular concentrations as described in the text. 
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Table 4. Applications, strengths and limitations of various in vitro transporter assay systems 
In Vitro System Applications Strengths Limitations 
Membrane Vesicles • Evaluate drug interactions with 
efflux transporters (ABC-
transporters) 
• Determine substrate specificity 
and identify inhibitors 
• Good for compound with low Papp  
• Cytotoxic compounds do not impact 
the experimental system 
• High transporter expression levels in 
recombinant systems and transporter 
expression can be "titrated" in certain 
expression systems 
• Large batches can be prepared and 
cryopreserved for ready availability 
• Able to be preloaded with a variety of 
buffers and substances 
• Accurate determination of kinetics as 
substrates in incubation buffer have 
direct access to active sites 
• Not suitable for compounds with high 
Papp, or high non-specific binding 
• Relatively high rate of false 
negatives for substrate identification 
• Hypoglycosylation in insect cells may 
alter transport characteristics 
• Endogenous transport activity in the 
expression system may complicate 
data interpretation 
• Transporter activity varies from batch 
to batch 
• Special equipment is necessary if 
prepared in house (ultracentrifuge or 
nitrogen cavitation bomb) 
Recombinant cell 
lines expressing 
uptake transporters 
• Evaluate drug interactions with 
uptake transporters (OATPs, 
OCTs, OATs, NTCP)  
• Determine substrate specificity 
and identify inhibitors 
• Allows investigation of the 
characteristics of a single transporter 
• Stably transfected cell lines can be 
passaged for multiple use or 
cryopreserved 
• Low complexity 
• Endogenous transporter activity in 
host cells may complicate data 
interpretation 
• Generation and characterization of 
stable recombinant cell lines is time 
consuming (>1 month)  
• Transporter expression levels vary 
between laboratories 
Polarized cell 
monolayers 
• Evaluate drug transport by 
efflux transporters 
• Determine substrate specificity 
and identify inhibitors 
• Investigate the interplay 
between uptake and efflux 
transporters qualitatively 
• Transport is less influenced by non-
specific binding since only the 
compound crossing the cell monolayer 
is measured 
• Suitable to assess active transport 
versus diffusion  
• Endogenous transporter activity may 
complicate data interpretation 
• Mass balance needs to be assessed 
• Complicated kinetic studies  
• Not suitable for compounds with low 
Papp unless uptake transporter is co-
expressed 
Plated hepatocytes 
or hepatocytes in 
suspension 
• Evaluate drug uptake 
mediated by hepatic 
transporters 
• Identify inhibitors of active 
uptake  
• Identify transporters involved 
in initial uptake of drugs  
• Expression of various uptake 
transporters relatively close to in vivo 
• Allows assessment of contribution of 
multiple hepatic uptake transporters 
simultaneously 
• Cryopreserved or freshly isolated 
hepatocytes from the species of 
• Loss of cell polarity 
• No functional activity of canalicular 
efflux transporters 
• Rapid loss of metabolic activity in 
culture 
• Membrane integrity of suspended 
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interest can be used 
• Pools of human hepatocytes can be 
applied to eliminate inter-individual 
variability 
• Allows assessment of active uptake 
versus diffusion   
cryopreserved hepatocytes may be 
compromised 
Sandwich-cultured 
hepatocytes 
• Evaluate hepatic uptake/efflux 
and biliary excretion 
• Identify transporters and rate-
limiting steps involved in 
hepatobiliary drug disposition  
• Assess potential for drug-
induced cholestasis due to 
transporter inhibition 
• Investigate the interplay 
between uptake and efflux 
transporters  
• Assess intracellular 
concentration, Kpuu, and 
subcellular distribution of 
drugs 
• System mimics biliary excretion, and 
biliary clearance can be measured 
• Holistic system expressing both uptake 
and efflux transporters, metabolic 
enzymes, and regulatory machinery 
• Cryopreserved or freshly isolated 
hepatocytes from the species of 
interest can be used 
• Suitable to identify transporter 
inhibitors (both competitive and non-
competitive) and inducers 
• Demonstrated in vitro-to-in vivo 
correlations in preclinical species and 
humans 
• Requires time in culture for proper 
localization of transporters in 
appropriate membrane domains 
• Less suitable for low clearance 
compounds (especially if metabolism 
is involved) 
• Enzyme/transporter 
expression/activity may be 
modulated by culture conditions 
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Table 5. Flow Diagram: Integration of in vitro and in vivo data to determine the role of transporters in compound absorption, distribution, clearance, and DDIs 
 
Scientific 
Question 
Observations to Support In 
Vitro Transporter 
Investigations 
In Vitro Tools to Address 
Scientific Hypothesis 
Outcome of In Vitro Experiments Potential Follow-Up Studies 
• Uptake in models expressing  gut 
specific uptake transporters (e.g. 
PEPT1) 
• Mechanistic understanding of individual transporters 
• May be possible to understand structure-activity 
relationship (SAR) and obtain kinetic parameters for 
individual transporters  Does active uptake 
influence intestinal 
absorption? 
• Less than proportional oral PK 
profiles with increasing dose 
• High bioavailability despite low 
intrinsic permeability 
• Disconnect between measured in 
vivo absorption or Caco-2 
permeability and physicochemical 
parameters/in silico model 
predicting poor permeability 
• Caco-2 cells (Papp A-B ± 
inhibitors) 
• Explore potential impact of multiple transporters on 
oral absorption 
• Derive intrinsic passive permeability 
• Bi-directional efflux in single 
transfected polarized cell 
monolayers (e.g. MDR1 P-gp, 
BCRP, MRP2) 
• Mechanistic understanding of individual transporters 
• May be possible to understand SAR and generate 
kinetic parameters for individual transporters 
Absorption 
Does apical efflux 
limit intestinal 
absorption? 
• Greater than proportional oral PK 
with increasing dose. 
• Low oral bioavailability despite 
high solubility and permeability 
• Caco-2 Papp A-B with inhibitors or 
bi-directional efflux studies 
• Explore potential impact of multiple transporters on 
oral absorption and derive intrinsic passive 
permeability 
• Preclinical in vivo and ex-vivo studies (e.g. 
regional absorption models, IV/PO studies 
in transporter knockout mice/rats, portal 
vein cannulated studies) 
• Modeling software (using kinetic 
parameters, transporter abundance) to 
estimate clinical impact of active 
uptake/efflux on bioavailability 
Is intestinal apical 
secretion a possible 
clearance pathway? 
 
• Presence of compound in feces 
following an IV dose in bile duct 
cannulated animals 
• Bi-directional efflux in single 
transfected polarized cell 
monolayers (e.g. MDR1 P-gp, 
BCRP)  or Caco-2 cell monolayers 
• Identification of individual transporters 
• May be able to gain mechanistic insight, understand 
SAR and generate kinetic parameters for individual 
transporters 
• Preclinical in vivo and ex-vivo studies (e.g. 
regional absorption models, IV studies in 
transporter knockout mice/rats, portal vein 
cannulated studies, ADME studies with 
radiolabeled compound) 
• Clinical studies with isolated GI segment 
and fluid collection (46) 
Does active hepatic 
uptake influence the 
distribution of 
compound to the 
liver or contribute to 
systemic clearance?  
• Under-prediction of in vivo intrinsic 
clearance (Clint) from in vitro 
metabolic clearance  
• High unbound liver: plasma ratios; 
can be important to understand 
when liver is the target for efficacy 
or if there is evidence of liver 
specific toxicity 
• Initial uptake in suspended or SCH 
hepatocytes; test whether 
transport is saturable, and study 
effect of inhibitors 
• Uptake in single transfected cells 
with specific transporters (e.g. 
OATP1B1, OATP1B3, OATP2B1, 
OCT1, NTCP) 
• Determine whether active uptake is significant. May 
be able to use selective inhibitors to separate role of 
individual transporters and generate kinetic 
parameters for individual transporters 
• IV studies determining liver and plasma 
exposure in wild-type and/or transporter 
knockout animals 
• Relative activity or expression factor 
approaches to determine relative 
contribution of individual transporters to 
uptake (47) 
• Determine Clbiliary and biliary 
excretion index (BEI) in sandwich-
cultured hepatocytes 
• Determine whether biliary secretion is important for 
parent compound and/or metabolites 
• Consider use of selective inhibitors to assess role of 
individual transporters 
 Distribution 
and 
Clearance 
Does transporter-
mediated biliary 
excretion contribute 
to systemic 
clearance? 
• Elimination of parent drug in feces 
after IV dose 
• Under-prediction of Clin vivo from in 
vitro metabolic clearance assays in 
microsomes/hepatocytes 
• Transport studies in MRP2, BCRP, 
BSEP, MATE, and MDR1 P-gp 
polarized cell monolayers 
• Transport in membrane vesicles 
• Identification of individual transporters 
• May be able to gain mechanistic insight, understand 
SAR, and generate kinetic parameters 
• Pre-clinical in vivo studies with bile duct 
cannulated rat or knockout mouse/rat 
transporter studies 
• Use in vitro data as input for PBPK-based 
prediction models 
• Clinical studies using CHOL-ect catheter or 
Loc-I-Gut with isolated GI segment and fluid 
collection (46) 
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Is active renal 
secretion 
contributing to 
systemic clearance? 
 
 
• Pre-clinical in vivo renal 
clearance > fu x GFR 
• Uptake in single transfected cells 
(e.g. OAT1, OAT3, OCT2) 
• Transwell studies with double 
transfected cells expressing relevant 
uptake and efflux transporters (e,g, 
OATPs, MRP2, OAT4, BCRP, MATEs, 
and MDR1 P-gp) 
• Transport in membrane vesicles 
• Mechanistic understanding of individual 
transporters 
• May be able to understand SAR and generate 
kinetic parameters for individual transporters 
 
Is there evidence 
for active renal re-
absorption? 
• Pre-clinical in vivo renal clearance 
<fu x GFR. 
• Uptake in single transfected cell 
lines (e.g. PEPT1/2, OAT4, URAT1) 
• Mechanistic understanding of individual 
transporters 
• Pre-clinical in vivo studies in transporter 
knockout mice or rats 
• Correlation to renal Clin vivo  data to support 
renal elimination hypothesis 
  Distribution 
and 
Clearance 
Is active efflux 
preventing a 
compound from 
crossing the blood 
brain barrier? 
• Lack of pharmacological activity 
when compounds potent against a 
CNS target are administered in vivo 
• Low unbound brain:plasma ratio 
• Measure transport in transfected 
cell monolayers (e.g. MDR1 P-gp, 
BCRP)  
• Mechanistic understanding of individual 
transporters 
• Measure efficacy and/or brain:plasma ratios  
in P-gp (Mdr1a/b), Bcrp or triple (Mdr1a/b, 
Bcrp) knockout mice or rats 
Is compound a 
potential 
"perpetrator" of a 
transporter-
mediated drug 
interaction? 
• Co-administer drug with known 
transporter substrates with a 
narrow therapeutic index 
• History of DDI from compounds 
within the same chemical class 
• Inhibition studies in transfected cells 
or vesicles 
• Inhibition of key transporters involved in the 
disposition of known administered co-
medications 
• Generation of kinetic parameters (e.g. IC50, Ki) 
• Dynamic modeling or static calculation (e.g. R-
value, [I1]/IC50, [I2]/IC50) measurements using 
in vitro kinetic parameters to estimate DDI risk 
• For OCT2/MATE inhibitors, clinical elevations 
in serum  creatinine but not cystatin C may 
serve as a biomarker for DDI potential (48) 
Is compound a 
potential "victim" of 
a transporter-
mediated drug 
interaction? 
• Results from absorption, 
distribution, or clearance data in 
this table 
• History of transporter involvement 
in drug disposition within the same 
chemical class 
• Use in vitro tools from other 
questions in this table (e.g. 
absorption, clearance and 
distribution) to determine whether 
the compound is a substrate 
• Follow-up inhibition studies with 
appropriate inhibitors 
• Identification of transporters that may be 
involved in compound absorption, distribution 
and clearance 
• May generate kinetic parameters for individual 
transporters 
• Dynamic modeling to determine clinical 
relevance (e.g. >25% of parent compound 
excreted in bile or urine) 
• Integration of data to understand alternate 
clearance pathways/fraction transported 
Can inhibition of 
transporters 
increase the risk for 
hyper-
bilirubinemia?* 
• Clinical hyperbilirubinemia 
• Preclinical toxicology results 
showing increased (conjugated) 
bilirubin levels 
• OATP1B1, OATP1B3, OATP2B1 and 
MRP2 inhibition studies in 
transfected cell lines and vesicles 
• Inhibition of bilirubin transport in 
sandwich-cultured hepatocytes 
• Identification of transporter(s) that may 
contribute to altered bilirubin disposition 
• Generation of kinetic parameters (e.g. IC50, Ki)  
• Clinical measurement of indirect 
(unconjugated) and direct (conjugated) 
bilirubin may help determine whether effects 
are on uptake, efflux, or both 
• UGT1A1 inhibition studies may increase 
understanding of unconjugated bilirubin 
elevations 
 Drug 
Interactions 
Can inhibition of 
transporters 
increase the risk for 
drug-induced 
cholestasis?* 
• Previous history of clinical 
cholestasis for compounds within 
the same chemical class 
• Preclinical toxicology results 
showing elevated serum bile acids 
• BSEP inhibition in vesicles 
• Inhibition of bile acid transport in 
sandwich-cultured hepatocytes 
• Potential for compound to alter bile acid 
disposition in the liver 
• Inhibition of NTCP and OATP to rule out bile 
acid uptake inhibition 
• Inhibition of other hepatic bile acid 
transporters 
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*Several mechanisms may contribute to drug-induced cholestasis and conjugated hyperbilirubinemia.  Inhibition of transporters alone does not 
always result in clinical symptoms. Additional experiments and clinical monitoring should be conducted to assess the potential for occurrence of 
these adverse events.  References listed in this table are located in supplementary material available online. 
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Figure 1 
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Figure 2 
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Figure 3 
 
 
 
 
